Physician profile
Erika Levine
NPI 1487742508
$1,708.64
in general payments reported to CMS, 2019-2025
24 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $77.58 · 2021: $270 · 2022: $366 · 2023: $455 · 2024: $257 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.18 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $175.89 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $168.29 | 2019-2024 | |
| Abbvie INC. | $150.89 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $144.37 | 2019-2024 | Siliq, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $128.42 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $116.42 | 2019-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $104.17 | 2019-2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $94.91 | 2020-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $92.33 | 2021 | |
| Incyte Corporation | $81.55 | 2022-2024 | Opzelura |
| Lilly USA, LLC | $74.74 | 2019-2024 | Olumiant, Taltz |
| Ucb, INC. | $68.60 | 2020-2022 | |
| Arcutis Biotherapeutics, INC. | $62.13 | 2023-2024 | Zoryve |
| Almirall LLC | $45.25 | 2019-2022 | |
| Amgen INC. | $33.51 | 2022-2025 | Otezla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $31.75 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Dermavant Sciences, INC. | $28.94 | 2024 | Vtama |
| Genentech USA, INC. | $27.97 | 2023-2024 | Xolair |
| Genzyme Corporation | $21.81 | 2025 | |
| Mayne Pharma Commercial LLC | $15.16 | 2020 | |
| Botanix Sb INC | $14.40 | 2025 | Sofdra |
| Journey Medical Corporation | $13.39 | 2022 | |
| Pfizer INC. | $11.72 | 2021 | |
| Organon LLC | $2.03 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.